Effect of Intralymphatic Immunotherapy

• Status: Completed
• Trial end date: 2017-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators want to investigate whether specific immunotherapy can be delivered directly into a lymph node. The investigators think that a direct introduction of allergen to the antigen presenting cells in the lymph node a give a strong immune response and that this can change the number of injections needed in allergen immunotherapy. The investigators do measurements of clinical effect and a variety of paraclinical test to see if the investigators can find af biomarker of successful specific immune therapy of grass allergy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Aarhus

Criteria

Inclusion Criteria:

• Allergic rhinitis to grass pollen, more than 3 mm reaction at skin prick test for grass, age between 18 and 40 years.

Exclusion Criteria:

• Uncontrolled asthma.

• Severe asthma with post bronchodilator test forced expiratory volume at 1 second less than 70% of expected.

• Severe co morbidity. Allergy to Fenol or Aluminium hydroxid.

• Any autoimmune diseases. Treatment with beta blocking medicine.

• Any heart diseases.

• Severe arterial hypertension. Kidney failure.

• Known malignancy. Known pregnancy.